SG11201709122VA - Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases - Google Patents

Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases

Info

Publication number
SG11201709122VA
SG11201709122VA SG11201709122VA SG11201709122VA SG11201709122VA SG 11201709122V A SG11201709122V A SG 11201709122VA SG 11201709122V A SG11201709122V A SG 11201709122VA SG 11201709122V A SG11201709122V A SG 11201709122VA SG 11201709122V A SG11201709122V A SG 11201709122VA
Authority
SG
Singapore
Prior art keywords
treatment
diseases
prevention
attenuated influenza
oncological
Prior art date
Application number
SG11201709122VA
Other languages
English (en)
Inventor
Andrei Yurievich Egorov
Boris Ferko
Artem Alexandrovich Krokhin
Yulia Romanovna Romanova
Original Assignee
(«Pharmenterprises Biotech» Ltd Liability Company)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by («Pharmenterprises Biotech» Ltd Liability Company) filed Critical («Pharmenterprises Biotech» Ltd Liability Company)
Publication of SG11201709122VA publication Critical patent/SG11201709122VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201709122VA 2015-11-06 2016-11-03 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases SG11201709122VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2015147703A RU2628690C2 (ru) 2015-11-06 2015-11-06 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний
PCT/RU2016/050066 WO2017078577A2 (ru) 2015-11-06 2016-11-03 Аттенуированные гриппозные векторы для профилактики и/или лечения инфекционных заболеваний, а также для лечения онкологических заболеваний

Publications (1)

Publication Number Publication Date
SG11201709122VA true SG11201709122VA (en) 2017-12-28

Family

ID=58662984

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201709122VA SG11201709122VA (en) 2015-11-06 2016-11-03 Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases

Country Status (15)

Country Link
US (1) US10392604B2 (enExample)
EP (1) EP3382010A4 (enExample)
JP (1) JP6692835B2 (enExample)
KR (1) KR102604877B1 (enExample)
CN (1) CN108026515B (enExample)
AU (1) AU2016350939B9 (enExample)
CA (1) CA2991023C (enExample)
CU (1) CU24580B1 (enExample)
IL (1) IL255259B (enExample)
MA (1) MA43314A (enExample)
MX (1) MX380393B (enExample)
RU (1) RU2628690C2 (enExample)
SG (1) SG11201709122VA (enExample)
UA (1) UA125333C2 (enExample)
WO (1) WO2017078577A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217139A1 (ru) * 2017-05-26 2018-11-29 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний
AU2018392799A1 (en) 2017-12-22 2020-05-28 Codagenix, Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
CA3091508A1 (en) 2018-03-08 2019-09-12 Codagenix Inc. Attenuated flaviviruses
WO2020051766A1 (zh) 2018-09-11 2020-03-19 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
KR102370100B1 (ko) * 2019-02-15 2022-03-07 아이디바이오 주식회사 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신
RU2726106C1 (ru) * 2019-07-18 2020-07-09 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8-NS124-TB10.4-2A-HspX и способ специфической профилактики туберкулеза легких с использованием вакцины мукозального применения на его основе
AU2021342299A1 (en) * 2020-09-11 2023-04-13 The United States Of America, As Represented By The Secretary Of Agriculture Compositions and methods of use thereof for prevention and treatment of influenza infections
AU2021378792A1 (en) * 2020-11-11 2023-05-04 California Institute Of Technology Multivalent carriers and related vaccine compositions
CN113430178B (zh) * 2021-06-21 2022-10-11 武汉大学 一种表达ii型单纯疱疹病毒蛋白的重组流感病毒株及其制备方法与应用
WO2025041889A1 (ko) * 2023-08-24 2025-02-27 성신여자대학교 연구산학협력단 외래 항원을 발현하는 재조합 인플루엔자 바이러스 벡터 및 이를 포함하는 백신 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1085904E (pt) * 1998-06-12 2013-03-05 Sinai School Medicine Vírus de cadeia negativa atenuados com actividade antagonista do interferão alterada, para utilização como vacinas e produtos farmacêuticos
US6468544B1 (en) * 1998-06-12 2002-10-22 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
WO2001064860A2 (en) * 2000-03-02 2001-09-07 Polymun Scientific Immunbiologische Forschung Gmbh Recombinant influenza a viruses
US7037707B2 (en) * 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
US7709190B2 (en) * 2005-12-02 2010-05-04 Board Of Regents, The University Of Texas System Influenza A virus vaccines and inhibitors
EP2048237A1 (en) * 2007-10-05 2009-04-15 Avir Green Hills Biotechnology Research Development Trade Ag Replication deficient Influenza virus for the expression of heterologous sequences
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
WO2011014504A1 (en) * 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
CA2805505C (en) * 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
WO2011130652A2 (en) * 2010-04-15 2011-10-20 George Baer Compositions and methods for vaccinating humans and animals against enveloped viruses
JP2013531496A (ja) * 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えｒｎａウイルス及びその使用
CN103282375B (zh) * 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
EP2708552A1 (en) * 2012-09-12 2014-03-19 Medizinische Universität Wien Influenza virus

Also Published As

Publication number Publication date
AU2016350939B2 (en) 2021-07-08
WO2017078577A3 (ru) 2017-06-29
BR112017025435A8 (pt) 2019-08-20
AU2016350939B9 (en) 2021-07-22
MX380393B (es) 2025-03-12
MA43314A (fr) 2018-10-03
IL255259A (en) 2018-04-30
JP6692835B2 (ja) 2020-05-13
AU2016350939A1 (en) 2017-11-23
BR112017025435A2 (pt) 2018-09-11
AU2016350939A2 (en) 2018-02-08
CA2991023A1 (en) 2017-05-11
US20180245052A1 (en) 2018-08-30
EP3382010A2 (en) 2018-10-03
US10392604B2 (en) 2019-08-27
WO2017078577A2 (ru) 2017-05-11
UA125333C2 (uk) 2022-02-23
RU2628690C2 (ru) 2017-08-21
CN108026515A (zh) 2018-05-11
JP2018531578A (ja) 2018-11-01
HK1251616A1 (zh) 2019-02-01
CN108026515B (zh) 2022-03-11
MX2017015462A (es) 2018-03-07
KR20180067464A (ko) 2018-06-20
CU24580B1 (es) 2022-02-04
EP3382010A4 (en) 2019-03-27
CU20180035A7 (es) 2018-07-05
IL255259B (en) 2020-03-31
CA2991023C (en) 2025-05-13
RU2015147703A (ru) 2017-05-16
KR102604877B1 (ko) 2023-11-23

Similar Documents

Publication Publication Date Title
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL255259B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
IL246449B (en) Conjugated 6-heteroaryl dihydropyrimidines for the treatment and prevention of hepatitis b virus infection
ZA201708039B (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
ZA201705633B (en) A new quinoline derivative for use in the treatment and prevention of viral infections
IL263368A (en) Prevention and treatment of viral infections
GB201611712D0 (en) Methods and compounds for the treatment or prevention of severe or persistent influenza
ZA201705634B (en) Quinoline derivatives for use in the treatment or prevention of viral infection
IL249660B (en) Methods for treating hepatitis b virus and hepatitis d virus infections
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
GB201413530D0 (en) Treatment and prevention of malaria
PL3197556T3 (pl) KOMPOZYCJA DO ZAPOBIEGANIA l/LUB LECZENIA OBJAWÓW ALERGII
LT3360580T (lt) Genetinio gydymo būdas, naudojant aav-xbp1s/gfp virusą ir jo panaudojimas amiotrofinės šoninės sklerozės prevencijai ir gydymui
SG11201705889VA (en) Prevention or Treatment of Uratic or Gouty Diseases
GB201522329D0 (en) Use of adjuvants for the prevention and/or treatment of autoimmune diseases
SMT202400253T1 (it) Agenti pan-genotipici contro influenzavirus e metodi per usare gli stessi
GB201615035D0 (en) Treatment and prevention of viral infection
PT3095866T (pt) Agente de profilaxia e terapia de infeções virais
ZA201803649B (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases
PL3490604T3 (pl) Środek leczniczy do leczenia i/lub zapobiegania endometriozie
GB201520019D0 (en) The genome and self-evolution of AI
GB201522828D0 (en) Prevention and treatment of glaucoma
AU2014900488A0 (en) Agents and methods for inhibiting virus infection